Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

The multiple sclerosis functional composite: a clinically meaningful measure of disability.

Polman CH, Rudick RA.

Neurology. 2010 Apr 27;74 Suppl 3:S8-15. doi: 10.1212/WNL.0b013e3181dbb571. Review.

PMID:
20421572
2.

Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.

Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE, Benedict RH.

Mult Scler. 2010 Feb;16(2):228-37. doi: 10.1177/1352458509354552. Epub 2009 Dec 22.

PMID:
20028710
3.

[Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].

Mezei Z, Bereczki D, Csiba L, Csépány T.

Ideggyogy Sz. 2006 Nov 20;59(11-12):442-7. Hungarian.

PMID:
17203882
4.

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN.

Arch Neurol. 2001 Jun;58(6):961-7.

PMID:
11405811
5.

[Application of the Multiple Sclerosis Functional Composite in Debrecen].

Mezei Z, Bereczki D, Csiba L, Csépány T.

Ideggyogy Sz. 2005 Mar 20;58(3-4):113-8. Hungarian.

PMID:
15887414
6.

The reliability of the MSFC and its components.

Rosti-Otajärvi E, Hämäläinen P, Koivisto K, Hokkanen L.

Acta Neurol Scand. 2008 Jun;117(6):421-7. Epub 2007 Dec 12.

PMID:
18081910
7.

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B, Mass MK, Miller D, Simonian NA.

Neurology. 2001 May 22;56(10):1324-30.

PMID:
11376182
8.

Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.

Waldman AT, Chahin S, Lavery AM, Liu G, Banwell BL, Liu GT, Balcer LJ.

Mult Scler Relat Disord. 2016 Nov;10:73-78. doi: 10.1016/j.msard.2016.08.012. Epub 2016 Aug 26.

9.

Clinical outcome measures for research in multiple sclerosis.

Balcer LJ.

J Neuroophthalmol. 2001 Dec;21(4):296-301. Review.

PMID:
11756863
10.

Paced visual serial addition test in multiple sclerosis.

Nagels G, Geentjens L, Kos D, Vleugels L, D'hooghe MB, Van Asch P, Vuylsteke K, De Deyn PP.

Clin Neurol Neurosurg. 2005 Apr;107(3):218-22.

PMID:
15823678
11.

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.

Baier ML, Cutter GR, Rudick RA, Miller D, Cohen JA, Weinstock-Guttman B, Mass M, Balcer LJ.

Neurology. 2005 Mar 22;64(6):992-5.

PMID:
15781814
13.

MS functional composite: relation to disease phenotype and disability strata.

Kalkers NF, de Groot V, Lazeron RH, Killestein J, Adèr HJ, Barkhof F, Lankhorst GJ, Polman CH.

Neurology. 2000 Mar 28;54(6):1233-9.

PMID:
10746590
14.

Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.

Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS.

Arch Neurol. 2000 Sep;57(9):1319-24.

PMID:
10987899
15.

Assessing disability progression with the Multiple Sclerosis Functional Composite.

Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.

Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212.

PMID:
19667023
16.
17.

Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.

Kolind S, Seddigh A, Combes A, Russell-Schulz B, Tam R, Yogendrakumar V, Deoni S, Sibtain NA, Traboulsee A, Williams SC, Barker GJ, Brex PA.

Neuroimage Clin. 2015 Oct 3;9:574-80. doi: 10.1016/j.nicl.2015.10.002. eCollection 2015.

18.

Intrarater and interrater reliability of the MS functional composite outcome measure.

Cohen JA, Fischer JS, Bolibrush DM, Jak AJ, Kniker JE, Mertz LA, Skaramagas TT, Cutter GR.

Neurology. 2000 Feb 22;54(4):802-6.

PMID:
10690966
19.

Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.

Brochet B, Deloire MS, Bonnet M, Salort-Campana E, Ouallet JC, Petry KG, Dousset V.

Mult Scler. 2008 Nov;14(9):1242-9. doi: 10.1177/1352458508094398. Epub 2008 Jul 24.

PMID:
18653737
20.

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators.

Neurology. 2002 Sep 10;59(5):679-87.

PMID:
12221157

Supplemental Content

Support Center